SkinBit Raises $6M for Skin Cancer Screening Technology

A significant advancement in early skin cancer detection is on the horizon, as healthtech startup SkinBit has successfully closed a $6 million pre-seed funding round. This capital infusion, backed by prominent investors including Boost VC, Cleo Capital, Manna Ventures, and Profluent Capital, along with notable figures like Lyft co-founder Logan Green and nine board-certified dermatologists, will fuel the expansion of its innovative full-body skin imaging technology.

SkinBit aims to revolutionize routine dermatological assessments by deploying advanced scanning devices within clinics nationwide. These systems are designed to capture comprehensive, high-resolution images of a patient's entire skin surface in approximately 20 minutes. The captured data will be meticulously reviewed by dermatologists and stored to establish a patient-specific, longitudinal record. This historical data is crucial for tracking subtle changes over time, a critical factor in identifying potentially cancerous lesions that might otherwise be missed during traditional, less data-intensive examinations.

The impetus behind SkinBit stems from a personal experience of its co-founder, Jonathan Benassaya, who previously co-founded the music streaming service Deezer. Benassaya's own melanoma diagnosis in 2020, discovered serendipitously by a dermatologist, highlighted the limitations of current screening methods. "Health shouldn't rely on luck," Benassaya stated, emphasizing the need for a more systematic and data-driven approach to skin health monitoring. Skin cancer, the most prevalent cancer in the U.S. with approximately 5.4 million diagnoses annually, sees a concerning 42% increase in new melanoma cases over the past decade, underscoring the urgency for improved detection strategies.

The company is addressing a critical access gap in dermatological care. With an average wait time of 34.5 days for an appointment and a significant shortage of dermatologists, particularly in rural areas where 88% of counties lack a specialist, timely skin cancer screening remains a challenge. SkinBit's distributed network of scanners intends to alleviate some of this pressure by providing a more accessible and efficient screening process. By equipping dermatology practices, longevity clinics, and med spas with its technology, SkinBit seeks to augment the capabilities of dermatologists, offering them richer patient data to enhance diagnostic precision and potentially broaden their patient throughput.

This initiative aligns with a broader trend in consumer health towards continuous monitoring and data accumulation, mirroring advancements seen with wearables tracking cardiovascular health and sleep. SkinBit's model focuses on creating a robust, patient-owned visual history of their skin, enabling comparisons that are vital for early detection. The strategic addition of medical expertise, including Dr. Justin Ko, Chief of Medical Dermatology at Stanford, and Dr. Sancy Leachman, former chair of dermatology at Oregon Health & Science University, further solidifies the company's commitment to clinical rigor and data-driven innovation.

With plans to launch its first three locations in 2026 and expand to 15 by the end of 2027, SkinBit is poised to make a substantial impact. The company reports a waitlist exceeding 5,000 individuals, indicating strong market demand for its novel approach to skin cancer screening. This funding will be instrumental in scaling operations, refining the technology, and establishing SkinBit as a leader in proactive skin health management.